Clopidogrel
Quick Facts
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Non-ST-elevation ACS (UA / NSTEMI) — to reduce rate of MI and stroke | Adults; managed medically or with coronary revascularization (PCI/CABG) | Adjunctive — administered with aspirin | FDA Approved |
| ST-elevation MI (STEMI) — to reduce rate of MI and stroke | Adults managed medically | Adjunctive — administered with aspirin | FDA Approved |
| Recent MI, recent ischemic stroke, or established peripheral arterial disease — to reduce rate of MI and stroke | Adults | Monotherapy | FDA Approved |
Clopidogrel is the prototype second-generation thienopyridine and was the first oral P2Y12 antagonist to demonstrate cardiovascular benefit in a contemporary setting. Its FDA-approved indications fall into two evidence streams: acute coronary syndrome (ACS), where the registration trials CURE (NSTEMI/UA) and COMMIT (STEMI medically managed) established benefit when added to aspirin; and secondary prevention in stable atherosclerotic disease (recent MI, recent ischemic stroke, or established PAD), where CAPRIE established a marginal advantage of clopidogrel monotherapy over aspirin alone. The FDA-approved STEMI indication is for medically managed patients — but in current practice, clopidogrel is also used for STEMI patients undergoing primary PCI, with prasugrel and ticagrelor preferred where not contraindicated per the 2021 ACC/AHA/SCAI revascularization guideline.
The CHARISMA trial (clopidogrel + aspirin vs aspirin alone in patients with vascular disease or multiple risk factors for atherosclerosis) was negative for the primary endpoint and showed increased bleeding — establishing that clopidogrel + aspirin is not appropriate for primary prevention or for stable atherosclerosis without an acute event or stenting indication.
Dual antiplatelet therapy (DAPT) after coronary stenting — duration depends on stent type, indication, and bleeding risk; typically 6–12 months after DES for stable CAD, and at least 12 months after DES for ACS, per the 2016 ACC/AHA DAPT focused update and 2021 ACC/AHA/SCAI revascularization guideline. Evidence: high (RCTs, guidelines).
Short-term DAPT (clopidogrel + aspirin × 21–90 days) after minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD² ≥4) — supported by the CHANCE and POINT trials and the 2021 AHA/ASA stroke prevention guideline (Class 1, Level A). DAPT should be initiated ideally within 12–24 hours of symptom onset and at least within 7 days, then continued 21–90 days followed by single antiplatelet therapy. CHANCE used 21 days of DAPT; POINT used 90 days of DAPT; pooled analysis suggests benefit is concentrated in the first 21 days, while bleeding accumulates beyond day 21. Evidence: high (RCTs).
Carotid artery stenting and other peripheral vascular interventions — typically combined with aspirin for 1–3 months. Evidence: moderate (extrapolation, society guidelines).
Aspirin-intolerant patients requiring antiplatelet therapy — clopidogrel monotherapy is a reasonable substitute. Evidence: moderate (CAPRIE).
Dosing
| Clinical Scenario | Loading Dose | Maintenance Dose | Duration | Notes |
|---|---|---|---|---|
| NSTEMI / UA — managed medically or with PCI | 300 mg orally × 1 | 75 mg once daily | Up to 12 months (typical) | Combined with aspirin per FDA label. PCI patients: 600 mg loading commonly used in clinical practice (off-label) for faster onset Without loading dose, antiplatelet effect is delayed by several days |
| STEMI — managed medically (FDA indication) | 300 mg orally × 1 | 75 mg once daily | ≥14 days; up to 12 months typical | Aspirin co-therapy required per FDA label In patients ≥75 years, the COMMIT protocol used 75 mg daily without a loading dose |
| STEMI undergoing primary PCI (off-label dosing) | 600 mg orally × 1 (clinical practice) | 75 mg once daily | 12 months typical | Prasugrel or ticagrelor preferred where not contraindicated per the 2021 ACC/AHA/SCAI guideline; clopidogrel reserved for those at higher bleeding risk or with contraindications to other P2Y12 inhibitors |
| Recent MI, recent ischemic stroke, or established PAD (CAPRIE indication) | None | 75 mg once daily | Long-term | Monotherapy (no aspirin needed). Onset of antiplatelet effect within 2 hours; steady state day 3–7 |
| DAPT after PCI with drug-eluting stent — stable CAD | Per ACS protocol if loading required | 75 mg once daily + aspirin 81 mg/day | 6 months minimum (DAPT guideline) | Shorter (1–3 months) acceptable in high bleeding risk; longer (≥12 months) considered in low bleeding risk per 2016 ACC/AHA DAPT guideline |
| Minor stroke (NIHSS ≤3) / high-risk TIA (off-label, AHA/ASA-endorsed) | 300 mg (CHANCE) or 600 mg (POINT) × 1 | 75 mg/day + aspirin × 21–90 days, then single antiplatelet therapy | 21–90 days DAPT, then SAPT | Initiate ideally within 12–24 h of symptom onset, at least within 7 days. AHA/ASA Class 1, Level A. Most US clinicians use 21-day DAPT (CHANCE) given accumulating bleeding risk beyond day 21 in pooled analyses |
CYP2C19 Genotype-Directed Dosing
The 2022 FDA boxed warning advises considering an alternative P2Y12 inhibitor (prasugrel or ticagrelor) in patients identified as CYP2C19 poor metabolizers (homozygous loss-of-function alleles, *2/*2, *2/*3, or *3/*3). A higher dose regimen (600 mg load, 150 mg daily) increases antiplatelet response in poor metabolizers, but the FDA notes that an appropriate dose has not been established in a clinical outcome trial.
The Clinical Pharmacogenetics Implementation Consortium (CPIC) 2022 guideline strengthened its pharmacogenomic recommendations:
- Poor metabolizers (PM, ~2% of White, ~4% of Black, ~14% of Chinese populations per FDA label): CPIC strongly recommends avoiding clopidogrel; use prasugrel or ticagrelor where not contraindicated.
- Intermediate metabolizers (IM): CPIC strongly recommends avoiding clopidogrel for ACS or PCI (upgraded from “moderate” to “strong” in the 2022 update); use an alternative P2Y12 inhibitor. CPIC explicitly does not support 150 mg daily dosing of clopidogrel in IMs. The Dutch Pharmacogenetics Working Group (DPWG) takes a different position, listing 150 mg daily (with 600 mg load) as one acceptable option for IMs undergoing PCI.
- Normal/rapid/ultrarapid metabolizers: standard clopidogrel dosing.
Renal & Hepatic Adjustment
Per the FDA label, no dosage adjustment is necessary for hepatic impairment. For renal impairment, the FDA label states experience is limited and provides no numerical adjustment, but notes that in patients with severe renal impairment (CrCl 5–15 mL/min) and moderate renal impairment (CrCl 30–60 mL/min), platelet inhibition was reduced (~25%) compared with healthy subjects. In clinical practice, no dose adjustment is made for renal impairment.
Periprocedural Dosing
For patients undergoing surgery with major bleeding risk: discontinue clopidogrel 5 days before the procedure per the FDA label, and resume as soon as hemostasis is achieved. For pregnancy: discontinue 5–7 days prior to labor, delivery, or neuraxial blockade. Platelet transfusion within 4 hours of a loading dose or 2 hours of a maintenance dose may be less effective — wait if possible to maximize transfusion benefit.
Because clopidogrel binds the P2Y12 receptor irreversibly, its antiplatelet effect persists for the lifespan of the affected platelets (7–10 days). Bleeding time generally returns to baseline ~5 days after discontinuation as new platelets enter circulation. This explains both the 5-day pre-procedure withdrawal and the several-day delay to full effect without a loading dose. The 300 mg load drives the active metabolite Cmax to twice the level achieved by 75 mg at steady state, producing meaningful platelet inhibition within 2 hours rather than 3–7 days. In ACS, the loading dose is therefore not optional unless rapid antiplatelet effect is unimportant.
Pharmacology
Mechanism of Action
Clopidogrel is a prodrug. Its parent molecule has no antiplatelet activity. Following oral absorption, approximately 85% of circulating metabolites result from esterase-mediated hydrolysis to an inactive carboxylic acid derivative; the remaining metabolism proceeds through a two-step CYP450-mediated oxidation, first to a 2-oxo-clopidogrel intermediate and then to an unstable thiol metabolite. Both steps depend principally on CYP2C19, with smaller contributions from CYP1A2, CYP2B6, and CYP3A. The active thiol metabolite has a plasma half-life of only about 30 minutes but binds irreversibly via a disulfide bond to a cysteine residue on the P2Y12 ADP receptor of platelets, abolishing ADP-mediated platelet activation and downstream glycoprotein IIb/IIIa-dependent fibrinogen binding for the lifespan of the platelet (7–10 days).
The two-step CYP450 dependence is the basis of clopidogrel’s two key vulnerabilities: genetic loss-of-function CYP2C19 alleles (the boxed warning), and drug-mediated CYP2C19 inhibition (PPI interaction, particularly with omeprazole/esomeprazole). Both reduce active-metabolite formation and measurably reduce platelet inhibition.
At 75 mg/day at steady state, clopidogrel produces ~40–60% inhibition of ADP-induced platelet aggregation per FDA label. Onset of detectable platelet inhibition occurs ~2 hours after a loading dose and reaches steady state between days 3 and 7 of maintenance dosing without a load.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapidly absorbed; ≥50% bioavailability per FDA label (estimated from urinary excretion of metabolites); active metabolite Tmax 30–60 min after oral dose; active metabolite Cmax after 300 mg load is ~2× that of 75 mg at steady state; food does not meaningfully affect AUC of active metabolite (Cmax decreases ~57% but exposure is preserved) | Take with or without food. Loading dose required when rapid onset (within hours) is needed. Co-administered opioids (morphine) reduce active-metabolite AUC and Cmax by ~34% via slowed gastric emptying |
| Distribution | Parent and circulating metabolites bind reversibly to plasma proteins (high binding); active thiol metabolite binds irreversibly to platelet P2Y12 receptor; distribution to milk demonstrated in rats; human-milk distribution not characterized | Pharmacodynamic effect outlasts pharmacokinetic exposure because of irreversible target binding — explains the 7–10 day duration of action despite a 6-h parent half-life |
| Metabolism | ~85% of circulating metabolites are the inactive carboxylic acid (esterase pathway); CYP-mediated pathway converts clopidogrel to 2-oxo-clopidogrel and then to the active thiol metabolite (mainly CYP2C19; also CYP1A2, CYP2B6, CYP3A). Acyl-β-glucuronide metabolite is a strong CYP2C8 inhibitor | CYP2C19 is the principal activation enzyme — explains both the genetic boxed warning and the omeprazole interaction. CYP2C8 inhibition explains the 5.1-fold AUC increase in repaglinide co-administration |
| Elimination | Parent t½ ~6 h; active metabolite t½ ~30 min; ~50% of an oral dose excreted in urine, ~46% in feces over 5 days (largely as inactive metabolites); no parent drug detected unchanged in urine | No accumulation with daily dosing. Bleeding time normalizes ~5 days after discontinuation as platelets are replaced — this defines the 5-day pre-procedure withdrawal |
Side Effects
Bleeding — including life-threatening and fatal bleeding — is by far the dominant adverse reaction with clopidogrel. The FDA label tabulates bleeding rates from the major registration trials (CURE, COMMIT, CAPRIE), allowing transparent quantitative comparison. Per the FDA label, in CURE and CHARISMA there was no difference in non-bleeding adverse reaction rates between clopidogrel and placebo (both with aspirin); in CAPRIE, the only non-bleeding adverse reaction reported significantly more frequently with clopidogrel was pruritus. Other low-frequency events captured through postmarketing surveillance are listed in the FDA label and include rare but clinically critical reactions (TTP, severe cutaneous reactions, blood dyscrasias).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Combined major + minor bleeding (CURE, clopidogrel + aspirin) | 8.8% (3.7% major + 5.1% minor) vs ~5.1% with placebo + aspirin (FDA label CURE) | Most events were mucocutaneous (epistaxis, bruising, GI). Major bleeding 3.7% vs 2.7% placebo; minor bleeding 5.1% vs 2.4% placebo |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Major bleeding (CURE, clopidogrel + aspirin) | 3.7% vs 2.7% placebo + aspirin (FDA label) | Primarily GI and at puncture sites. Includes life-threatening bleeding (2.2% vs 1.8%) |
| Minor bleeding (CURE, clopidogrel + aspirin) | 5.1% vs 2.4% placebo + aspirin (FDA label) | Defined as bleeding leading to interruption of study medication |
| Any noncerebral bleeding (COMMIT STEMI) | 3.9% vs 3.4% placebo + aspirin (p=0.004) (FDA label) | STEMI population had less excess bleeding than NSTEMI/UA — possibly reflecting shorter duration (28 days vs up to 12 months) |
| GI hemorrhage (CAPRIE monotherapy) | 2.0% clopidogrel vs 2.7% aspirin (FDA label) | CAPRIE compared monotherapies; GI bleeding was lower with clopidogrel than aspirin |
| Bleeding requiring hospitalization (CAPRIE) | 0.7% clopidogrel vs 1.1% aspirin (FDA label) | Monotherapy comparison favored clopidogrel |
| Pruritus | More frequent vs aspirin in CAPRIE (FDA label) | Per the FDA label, the only non-bleeding adverse reaction reported significantly more frequently in CAPRIE. Often resolves with continued therapy or with antihistamines |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Life-threatening bleeding (CURE definition) | 2.2% clopidogrel + aspirin vs 1.8% placebo + aspirin (FDA label) | Anytime; risk highest first 30 days | Hold drug; supportive measures; platelet transfusion if hemodynamically required (less effective if given within 2 h of maintenance dose or 4 h of loading dose); urgent surgical / endoscopic intervention as indicated |
| Fatal bleeding | 0.2% in CURE — same as placebo (FDA label) | Anytime | Standard hemorrhage protocols; transfusion as needed |
| Intracranial hemorrhage | 0.1% in CURE; 0.4% on clopidogrel vs 0.5% on aspirin in CAPRIE (FDA label) | Anytime; risk amplified by trauma or anticoagulant co-therapy | Discontinue immediately; emergent neurosurgery consultation; platelet transfusion may be considered (the PATCH trial showed harm with platelet transfusion in spontaneous ICH on antiplatelets) |
| Thrombotic thrombocytopenic purpura (TTP) — labeled warning | Rare; sometimes after <2 weeks exposure (FDA postmarketing) | Days to weeks; can occur very early | Pentad: thrombocytopenia, microangiopathic hemolysis with schistocytes, fever, neurologic findings, renal dysfunction. Discontinue clopidogrel immediately; urgent plasmapheresis; ICU-level care. May be fatal |
| Hypersensitivity / anaphylaxis | Rare (FDA label; cross-reactivity reported with other thienopyridines) | First doses to weeks | Permanent discontinuation; standard anaphylaxis protocol; consider non-thienopyridine alternative (ticagrelor) |
| Severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, AGEP, DRESS, erythema multiforme) | Very rare (FDA postmarketing) | Days to weeks | Permanent discontinuation; urgent dermatology / burn-unit referral; supportive care |
| Blood dyscrasias (agranulocytosis, aplastic anemia, pancytopenia, acquired hemophilia A) | Very rare (FDA postmarketing) | Variable; typically weeks to months | Discontinue; hematology consultation; supportive care including transfusion and growth factors as needed |
| Acute liver failure / hepatitis | Very rare (FDA postmarketing) | Variable | Discontinue; recheck LFTs; gastroenterology / hepatology referral; do not rechallenge |
| Eosinophilic pneumonia / interstitial pneumonitis | Very rare (FDA postmarketing) | Weeks to months | Discontinue; HRCT, BAL, and pulmonology consultation; corticosteroids may be required |
| Insulin autoimmune syndrome (severe hypoglycemia) | Very rare (FDA postmarketing) | Variable | Discontinue clopidogrel; investigate fasting hypoglycemia; endocrinology referral. Insulin antibodies confirm diagnosis |
| Pancreatitis / colitis (including ulcerative or lymphocytic) | Rare (FDA postmarketing) | Variable | Discontinue; standard supportive care; do not rechallenge |
| Reason for Discontinuation | Approximate Frequency | Context |
|---|---|---|
| Bleeding (any clinically significant) | Most common | Often manageable by short interruption or PPI co-therapy (non-omeprazole). Permanent discontinuation reserved for life-threatening or recurrent bleeding |
| Pre-operative withdrawal | Common | FDA label requires 5-day interruption for major surgery. Premature stopping increases CV risk — restart as early as hemostasis allows |
| Pruritus, rash, GI intolerance | Uncommon | Switch to ticagrelor for ACS or aspirin alone in stable disease; thienopyridine cross-reactivity warrants caution with prasugrel |
| Hypersensitivity / serious cutaneous or hematologic reaction | Rare | Permanent discontinuation. Avoid all thienopyridines (prasugrel, ticlopidine); ticagrelor (cyclopentyltriazolopyrimidine) is structurally distinct |
The bleeding risk profile of clopidogrel is well-quantified by trial data and is dose-additive with aspirin, NSAIDs, anticoagulants, and SSRIs/SNRIs. Practical mitigation is structured: confirm baseline CBC and renal function before starting; co-prescribe a PPI (preferably pantoprazole, lansoprazole, or dexlansoprazole — not omeprazole or esomeprazole) for patients with prior GI bleeding or on chronic NSAIDs. For minor bleeding, short interruption suffices; for major bleeding, hold the drug, transfuse platelets if hemodynamically required (timed at least 2 hours after last maintenance dose to maximize benefit), and address the source. TTP is the unpredictable critical event — patients with new neurologic symptoms, fever, jaundice, or renal failure within the first 2 weeks of therapy require urgent CBC with peripheral blood smear; thrombocytopenia plus schistocytes mandates immediate plasmapheresis and is a permanent contraindication to thienopyridine rechallenge.
Drug Interactions
Clopidogrel’s clinically meaningful drug interactions cluster around three mechanisms: (1) CYP2C19 inhibition, which reduces formation of the active thiol metabolite and blunts platelet inhibition (the basis of the omeprazole/esomeprazole avoidance); (2) additive bleeding with other agents that affect hemostasis; and (3) CYP2C8 inhibition by clopidogrel’s acyl-β-glucuronide metabolite, which raises levels of CYP2C8 substrates such as repaglinide.
Monitoring
-
Bleeding Assessment (clinical)
Each clinic visit and any acute presentation
Routine Inspect for bruising, GI symptoms (melena, hematemesis, anemia symptoms), genitourinary bleeding, and prolonged bleeding from minor cuts or dental procedures. Most clinically meaningful events are mucocutaneous and managed conservatively. Major or recurrent bleeding warrants risk reassessment. -
Complete Blood Count (Hgb, platelets)
Baseline → 2–4 weeks → as clinically indicated
Routine in DAPT Check for occult bleeding (Hgb decline) and rare hematologic toxicity (thrombocytopenia of TTP, agranulocytosis, aplastic anemia). New onset of thrombocytopenia within 2 weeks of starting clopidogrel warrants peripheral blood smear and TTP workup. -
CYP2C19 Genotype
Once, before or shortly after initiation in selected patients
Trigger-based (boxed warning context) Per the boxed warning, tests are available to identify CYP2C19 poor metabolizers. CPIC 2022 strongly recommends avoiding clopidogrel in poor and intermediate metabolizers undergoing PCI for ACS. Consider genotyping in PCI patients of East/South Asian descent (higher LOF allele prevalence) and in those with stent thrombosis or recurrent ischemic events on clopidogrel. -
Platelet Reactivity Testing (VerifyNow, vasodilator-stimulated phosphoprotein index)
Generally not routinely recommended
Trigger-based / Research Routine platelet function testing is not endorsed by current guidelines (TROPICAL-ACS, ARCTIC, GRAVITAS — neutral or mixed results). May be considered in selected high-risk PCI cases or recurrent stent thrombosis on clopidogrel. -
Renal Function (creatinine, eGFR)
Baseline → with comorbid disease monitoring
Routine No specific dose adjustment, but severe renal impairment is associated with reduced platelet inhibition (~25% per FDA label). Renal disease independently increases bleeding risk. -
Adherence to therapy
Each clinic visit; especially first 12 months post-stent
Routine — critical Premature discontinuation increases CV events per FDA label, including the catastrophic event of stent thrombosis. Confirm patient understanding of duration; address cost barriers (clopidogrel is widely generic and inexpensive). -
Pre-procedure planning
Whenever surgery / dental work is planned
Trigger-based Per FDA label: discontinue clopidogrel 5 days before procedures with major bleeding risk; resume as soon as hemostasis is achieved. Many minor procedures (e.g., dental cleaning, cataract surgery, simple skin biopsies) can proceed without interruption based on procedural society guidance. -
TTP Symptom Awareness
First 2 weeks especially
Trigger-based Counsel patients to seek urgent care for unexplained fever, jaundice, severe headache, confusion, or oliguria. Lab workup: CBC with smear, LDH, indirect bilirubin, haptoglobin, creatinine.
For uncomplicated DAPT after PCI: baseline CBC, creatinine, and clinical bleeding history; recheck CBC at 2–4 weeks for delayed thrombocytopenia or anemia, then per indication. Reinforce adherence at every visit during the first 12 months. Plan procedural interruptions ≥5 days in advance and resume promptly. Consider CYP2C19 genotyping in PCI patients of East/South Asian descent or in those with stent thrombosis or recurrent events on clopidogrel.
Contraindications & Cautions
Absolute Contraindications (FDA Label)
- Active pathological bleeding — including peptic ulcer hemorrhage and intracranial hemorrhage.
- Hypersensitivity to clopidogrel or any component — anaphylaxis, angioedema, or severe cutaneous reactions to clopidogrel. Cross-reactivity has been reported among thienopyridines (clopidogrel, prasugrel, ticlopidine).
Relative Contraindications (Specialist Input or Class Switch Recommended)
- CYP2C19 poor metabolizer status (homozygous loss-of-function alleles) — boxed warning recommends considering prasugrel or ticagrelor instead.
- Concomitant omeprazole or esomeprazole — FDA label says “avoid concomitant use” because of significantly reduced antiplatelet activity.
- Recent intracranial hemorrhage — even after resolution, antiplatelet therapy carries elevated rebleed risk; multidisciplinary review required.
- High bleeding risk procedures within 5 days — per FDA label, interrupt for 5 days before elective major surgery.
- Severe thrombocytopenia (platelet count <50 × 10⁹/L) — relative contraindication; balance ischemic vs bleeding risk.
- Pregnancy at term / labor — FDA label advises discontinuation 5–7 days before delivery and avoidance of neuraxial blockade during clopidogrel use because of spinal hematoma risk.
- Active TTP or history of clopidogrel-associated TTP — permanent contraindication to clopidogrel and other thienopyridines.
- Severe hepatic dysfunction with coagulopathy — bleeding risk dominates the risk-benefit calculation, although the FDA label notes no PK adjustment is needed for hepatic impairment per se.
- Concomitant use with potent CYP2C19 inducers (e.g., rifampin) — increased active-metabolite levels and bleeding risk per FDA label.
- Concomitant repaglinide — clopidogrel raises repaglinide AUC 3.9–5.1 fold; FDA label recommends avoidance.
Use with Caution
- Older adults — bleeding risk rises with age; the FDA label notes no dosage adjustment is necessary, but bleeding rates in CURE were higher in patients ≥75.
- Severe renal impairment — reduced platelet inhibition (~25% per FDA label) plus increased bleeding risk from uremic platelet dysfunction.
- Patients on chronic NSAIDs, SSRIs/SNRIs, anticoagulants — additive bleeding risk per FDA label; ensure clear risk-benefit rationale.
- Recent ischemic stroke — caution with hemorrhagic transformation; combining with aspirin is acceptable for short-term DAPT in minor stroke/high-risk TIA per the AHA/ASA 2021 guideline.
- Recent neuraxial procedures or spinal/epidural anesthesia — risk of spinal hematoma; observe required intervals between clopidogrel and procedure per ASRA guidelines.
- Patients of East Asian or South Asian descent — higher prevalence of CYP2C19 LOF alleles; consider genotyping or alternative P2Y12 inhibitor in PCI/ACS settings.
The effectiveness of Plavix depends on conversion to an active metabolite by the cytochrome P450 system, principally CYP2C19. Plavix at recommended doses forms less of the active metabolite and therefore has a reduced effect on platelet activity in patients who are homozygous for nonfunctional CYP2C19 alleles (“CYP2C19 poor metabolizers”). Tests are available to identify these patients. Consider use of another platelet P2Y12 inhibitor in patients identified as CYP2C19 poor metabolizers.
Prevalence of poor metabolizer status: ~2% of White, ~4% of Black, and ~14% of Chinese patients per FDA label. The CPIC 2022 guideline strongly recommends an alternative P2Y12 inhibitor (prasugrel or ticagrelor where not contraindicated) in poor and intermediate metabolizers undergoing PCI for ACS.
Patient Counselling
Purpose of Therapy
Clopidogrel is a “blood thinner” that reduces the stickiness of platelets — the small blood cells that form clots. After a heart attack, stroke, or stent placement, those platelets can stick together inside narrowed arteries and cause another event. Clopidogrel makes that less likely. The benefit only appears if the medication is taken every day as prescribed: missing doses or stopping early is the most common reason patients have a second heart attack or a stent clot. Most patients take clopidogrel for 6 to 12 months after a stent or heart attack, and sometimes longer; the prescribing clinician will decide the exact duration.
How to Take
Take one 75 mg tablet once daily, with or without food, at the same time each day. If a dose is missed, take it as soon as it is remembered the same day; if it is nearly time for the next dose, skip the missed dose and take the next at the regular time — never double up. Do not stop clopidogrel without first speaking to the clinician who prescribed it, even if blood pressure feels normal or the heart attack feels long ago.
Sources
- U.S. Food and Drug Administration. Plavix® (clopidogrel) — Prescribing Information. Sanofi-Aventis U.S. LLC. Revised September 2022. accessdata.fda.gov Current US prescribing information; primary source for indications, boxed warning, dosing, contraindications, warnings, adverse reaction rates, drug interactions, and pharmacokinetic parameters cited in this monograph.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. March 12, 2010 (boxed warning addition). Regulatory action establishing the current CYP2C19 boxed warning.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339. Registration trial for the recent MI / recent stroke / PAD indication. Clopidogrel 75 mg vs aspirin 325 mg in 19,185 patients; 8.7% relative risk reduction in vascular events (p=0.045).
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502. doi.org/10.1056/NEJMoa010746 Registration trial for the NSTEMI/UA indication. 12,562 patients; 20% relative risk reduction in CV death/MI/stroke (9.3% vs 11.4%, p<0.001) with clopidogrel + aspirin vs aspirin alone.
- Chen ZM, Jiang LX, Chen YP, et al; COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607–1621. Registration trial for the medically managed STEMI indication. 7% relative risk reduction in death (p=0.029) and 9% in composite of death/MI/stroke (p=0.002).
- Bhatt DL, Fox KAA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–1717. doi.org/10.1056/NEJMoa060989 Negative trial of clopidogrel + aspirin in stable atherosclerosis / multiple risk factors. Established that DAPT is not appropriate for primary prevention. 6.9% vs 7.4% (p=0.22) for composite endpoint per FDA label.
- Wang Y, Wang Y, Zhao X, et al; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013;369(1):11–19. doi.org/10.1056/NEJMoa1215340 5,170 patients; 21-day DAPT (clopidogrel + aspirin) followed by clopidogrel alone for total 90 days. Stroke 8.2% vs 11.7% (HR 0.68, 95% CI 0.57–0.81, p<0.001); no excess hemorrhage.
- Johnston SC, Easton JD, Farrant M, et al; POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med. 2018;379(3):215–225. doi.org/10.1056/NEJMoa1800410 4,881 patients; 90-day DAPT regimen. Major ischemic events 5.0% vs 6.5% (HR 0.75, 95% CI 0.59–0.95, p=0.02), with major hemorrhage HR 2.32 (p=0.02). Pooled analysis with CHANCE showed benefit concentrated in first 21 days, supporting the 21-day DAPT duration most commonly used in US practice.
- Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015. doi.org/10.1056/NEJMoa0706482 Comparator trial: prasugrel reduced ischemic events but increased bleeding compared with clopidogrel in ACS-PCI patients.
- Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057. doi.org/10.1056/NEJMoa0904327 Comparator trial: ticagrelor reduced CV death/MI/stroke vs clopidogrel in ACS without increasing major bleeding (PLATO definition).
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–1115. doi.org/10.1016/j.jacc.2016.03.513 Foundational US guideline on DAPT duration after ACS, PCI, and stable CAD. Establishes 6–12 month duration as default with individualization for bleeding risk.
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(2):e21–e129. doi.org/10.1016/j.jacc.2021.09.006 Current US guideline on PCI antiplatelet therapy; positions ticagrelor and prasugrel ahead of clopidogrel for ACS/PCI where not contraindicated. Co-published in Circulation 2022;145(3):e18–e114.
- Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364–e467. doi.org/10.1161/STR.0000000000000375 Current AHA/ASA guideline. Class 1, Level A recommendation for DAPT (clopidogrel + aspirin) for 21–90 days, initiated ideally within 12–24 hours of symptom onset, after minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD² ≥4), followed by single antiplatelet therapy.
- Lee CR, Luzum JA, Sangkuhl K, et al; Clinical Pharmacogenetics Implementation Consortium (CPIC). CPIC guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update. Clin Pharmacol Ther. 2022;112(5):959–967. doi.org/10.1002/cpt.2526 Current CPIC pharmacogenomics guidance. Strong recommendation to avoid clopidogrel in CYP2C19 poor metabolizers and intermediate metabolizers undergoing PCI for ACS (strength upgraded from “moderate” to “strong” in 2022 for IMs); recommend prasugrel or ticagrelor as alternatives. CPIC does not endorse 150 mg clopidogrel daily dosing in IMs.
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(4):354–362. doi.org/10.1056/NEJMoa0809171 Pivotal study establishing that CYP2C19 reduced-function alleles (*2/*3) reduce active-metabolite formation, blunt platelet inhibition, and increase ischemic event rates — the evidence base for the boxed warning.
- Pereira NL, Farkouh ME, So D, et al; TAILOR-PCI Investigators. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324(8):761–771. doi.org/10.1001/jama.2020.12443 RCT evaluating CYP2C19 genotype-directed P2Y12 selection vs standard clopidogrel post-PCI. Did not meet primary endpoint at 12 months but showed benefit signals supporting genotyping in selected populations.